EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Lower-dose glucocorticoid therapy achieves comparable outcomes in Japanese patients with lupus nephritis

Yoshiyuki Abe iD, Ayako Makiyama, Kentaro Minowa iD, Saki Uchiyama, Masahiro Kogami, Motoki Takeuchi, Yoshiya Tanaka, Keiju Hiromura, Hiroki Hayashi, Kazuro Kamada, Yutaka Kawahito, Akiho Iwashita und 27 weitere

Lupus · 2026-07 · 35 (8) · 831-841

DOI: 10.1177/09612033261449985 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Lupus, online erschienen am 06.05.2026. Verfasst von Yoshiyuki Abe und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Rheumatology, Juntendo UniversitySchool of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Lupus Nephritis, Glucocorticoids. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Ministry of Health, Labour and Welfare of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the effectiveness of a lower initial glucocorticoid (GC) dose (0.4–0.6 mg/kg/day) compared to the conventional dose (0.8–1.2 mg/kg/day) in achieving complete renal response (CRR) at 12 months in Japanese patients with proliferative lupus nephritis (LN).

Methods

This multicentre, retrospective observational study analyzed data from 344 Japanese patients diagnosed with LN (class III or IV ± V) via renal biopsy. Patients were divided into two groups based on their initial dose of GC. 1:1 propensity score matching (PSM) based on key baseline variables, 23 patients were included in each group. The primary endpoint was CRR at 12 months, defined according to the BLISS-LN trial criteria. A non-inferiority margin of −10% was prespecified.

Results

After PSM, the CRR rate at 12 months was 87.0% in the low-dose group and 73.9% in the conventional-dose group (risk difference: 13.1%; 95% confidence interval [CI]: −9.4% to 35.6%), confirming statistical non-inferiority. While GC doses differed significantly during the initial 3 months, they became comparable between the groups after 6 months.

Conclusion

A reduced initial GC dose of 0.4–0.6 mg/kg/day achieved renal outcomes comparable to conventional dosing in Japanese patients with LN. Given the risks of GC toxicity, these findings may support the potential for lower-dose GC strategies in LN treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisGlucocorticoidsHumansFemaleRetrospective StudiesMaleJapanTreatment OutcomeAdultDose-Response Relationship, DrugMiddle AgedRemission InductionPropensity ScoreYoung AdultEast Asian People

Stichwörter der Autor:innen

complete renal responseglucocorticoidsimmunosuppressive therapylupus nephritisprednisolone

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • Department of Internal Medicine and Rheumatology, Juntendo UniversitySchool of Medicine, Tokyo, Japan.
  • Clinical Research and Trial Center, Juntendo UniversityHospital, Tokyo, Japan.
  • The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
  • Department of Nephrology and Rheumatology, Gunma UniversityGraduate School of Medicine, Maebashi, Japan.
  • Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan.
  • Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

ORCID-Profile: Yoshiyuki Abe, Kentaro Minowa, Hayato Shimizu, Shinsuke Yasuda, Nobuyuki Yajima, Michihito Kono, Takahiro Seno

Förderung

  • Ministry of Health, Labour and Welfare of Japan

Zitieren

APA

Abe, Y., Makiyama, A., Minowa, K., Uchiyama, S., Kogami, M., Takeuchi, M., Tanaka, Y., Hiromura, K., Hayashi, H., Kamada, K., Kawahito, Y., Iwashita, A., Kaname, S., Shimizu, H., Yasuda, S., Hiramoto, K., Maruyama, S., Yajima, N., Iwata, Y., …, & Tamura, N. (2026). Lower-dose glucocorticoid therapy achieves comparable outcomes in Japanese patients with lupus nephritis. Lupus, 35(8), 831-841. https://doi.org/10.1177/09612033261449985

Vancouver

Abe Y, Makiyama A, Minowa K, Uchiyama S, Kogami M, Takeuchi M, et al. Lower-dose glucocorticoid therapy achieves comparable outcomes in Japanese patients with lupus nephritis. Lupus. 2026;35(8):831-841. doi:10.1177/09612033261449985

BibTeX
@article{Abe2026,
  author = {Abe, Yoshiyuki and Makiyama, Ayako and Minowa, Kentaro and Uchiyama, Saki and Kogami, Masahiro and Takeuchi, Motoki and Tanaka, Yoshiya and Hiromura, Keiju and Hayashi, Hiroki and Kamada, Kazuro and Kawahito, Yutaka and Iwashita, Akiho and Kaname, Shinya and Shimizu, Hayato and Yasuda, Shinsuke and Hiramoto, Kazuoto and Maruyama, Shoichi and Yajima, Nobuyuki and Iwata, Yasunori and Matsumoto, Isao and Gono, Takahisa and Sato, Hiroko and Kubo, Satoshi and Ikeuchi, Hidekazu and Yuzawa, Yukio and Kono, Michihito and Seno, Takahiro and Onishi, Akira and Kawakami, Takahisa and Hosoya, Tadashi and Kaneko, Yuko and Kato, Sawako and Nakagawa, Shiori and Kondo, Yuya and Kuwana, Masataka and Ishii, Tomonori and Atsumi, Tatsuya and Ohmura, Koichiro and Tamura, Naoto},
  title = {Lower-dose glucocorticoid therapy achieves comparable outcomes in Japanese patients with lupus nephritis},
  journal = {Lupus},
  year = {2026},
  volume = {35},
  number = {8},
  pages = {831--841},
  doi = {10.1177/09612033261449985}
}
Kostenlos starten →